BlinkLab Limited (ASX:BB1), an innovative digital healthcare company specializing in smartphone-based AI-powered neurometric tests for diagnosing neurodevelopmental conditions, is excited to announce a significant research and clinical collaboration with Mental Care Group (MCG) in The Netherlands.
Key Points of the Partnership:
– Established partnership with the fifth largest outpatient mental health care provider in Europe, Mental Care Group.
– Partnership solidified after a successful pilot study conducted by Mental Care Group validated the effectiveness of BlinkLab’s technology in a clinical environment.
– Initial study involving 184 participants revealed that children with ADHD exhibit heightened sensory sensitivity, quantifiable through sound-evoked eyelid responses measured using the BlinkLab app.
– Collaboration aims to expedite BlinkLab’s pathway to regulatory approval in Europe and the U.S. for ADHD diagnosis and clinical implementation. Data collected from the ongoing clinical trial will contribute to a broader international ADHD study conducted by BlinkLab.
– Joint efforts between BlinkLab and MCG will focus on expanding and validating the application across a wider patient demographic and diverse range of diagnoses.
The emergence of smartphone-based digital sensory phenotyping presents a promising approach to diagnosing ADHD. BlinkLab’s innovative app conducts tests using the smartphone’s sensors to capture precise neurometric data. As part of the agreement, MCG plans to incorporate the BlinkLab app into their ADHD diagnostic processes. By analyzing behavioral and physiological responses collected through the app, BlinkLab aims to identify ADHD traits more efficiently, offering patients a faster, accessible, and objective assessment method. This collaboration underscores the potential of mobile health technology to advance mental health diagnostics globally.
About Mental Care Group:
Mental Care Group is the largest outpatient mental health care provider in the Netherlands and ranks fifth in Europe. With 150 facilities nationwide, the organization includes a network of psychologists, psychotherapists, and psychiatrists serving over 80,000 patients annually. MCG’s services encompass a wide range of mental health treatments for various age groups, including anxiety disorders, depression, PTSD, ADHD, and autism.
Known for its pioneering work in e-health, MCG offers patients multiple digital applications for online enrollment, intake assessments, and an extensive e-health library. Some patients also benefit from online or blended treatments. Through their collaboration with BlinkLab, MCG envisions a transformative future in healthcare where medical technology, AI, and digital tools revolutionize healthcare prediction, diagnosis, and early intervention. An example of this innovation is the recent launch of a patient portal developed in-house by MCG. This partnership aims to introduce innovative treatment and support methods, improving patient outcomes and setting new benchmarks in mental healthcare.
European Regulatory Approval and Clinical Integration:
BlinkLab and MCG will collaborate to secure regulatory approval for the diagnostic application and accelerate its adoption in clinical settings. The ongoing study in the Netherlands could potentially contribute to BlinkLab’s global ADHD study, opening up additional recruitment and testing opportunities.
For the full ASX Release, click the corresponding link provided.
(Note: This article contains information sourced from BlinkLab Limited, authorized for publication on Investing News Australia. It does not serve as financial advice, and readers are advised to conduct their own due diligence before acting on any information presented here. Please refer to the full disclaimer for more details.)
